We report the results of short-term tamoxifen treatment (20 mg two times a day orally) in 2 patients with metastatic medullary thyroid carcinoma. Patient A had a rapid tumor progression with development of Cushing's syndrome before initiation of tamoxifen treatment. Patient B had a slowly progressive course. In both cases, neither clinical nor biochemical improvement were observed, after 1 and 3 months of tamoxifen therapy, respectively.
ClarkeS.E.M., LazarusC.R., EdwardsS., MurbyB., ClarkeD.G., RodenT.M., FogelmanI., MaiseyN.: Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine, J. Nucl. Med., 28: 1820–1825, 1987.
2.
CuzickJ., AllenD., BaumM., BarretJ., ClarkG., KakkarV.: Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. Eur. J. Cancer, 29A: 15–21, 1992.
3.
ModiglianiE., CohenR., JoannidisS., Siame-MourotC., GulianaJ.M., CharpentierG.: Results of long-term continuos subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin. Endocrinol., 36: 183–186, 1992.
4.
NiimiS., HayakawaT., UchidaE., TanakaA.: Effects of glucocorticoids on deoxyribonucleic acid (DNA) synthesis stimulated by growth factors in cultured rat skin fibroblasts. Chem. Pharm. Bull., 38: 1633–1638, 1990.
5.
SamaanN.A., YangK.-P.P., SchultzP., HickeyR.C.: Diagnosis, management, and pathogenetic studies in medullary thyroid carcinoma syndrome. Henry Ford Hosp. Med. J., 37: 132–137, 1989.
6.
TronconeL., RufiniV., MontemaggiP., DanzaF.M., LasorellaA., MastrangeloR.: The diagnostic and therapeutic utility of radioidinated metaiodobenzylguanidine (MIBG). Five years of experience. Eur. J. Nucl. Med., 16: 325–335, 1990.
7.
WeberC.J., MarvinM., KrekunS., KoschitzkyT., KarpF., BensonM., FeindC.R.: Effects of tamoxifen and somatostatin on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: Tissue culture and nude mouse xenograft studies. Surgery, 109: 1065–1071, 1990.
